Jonathan Tobin

Jonathan Tobin is a seasoned investment professional with a focus on global biotech investments, currently serving as a Partner at Brandon Capital since August 2021. Additionally, Jonathan holds the position of Investor-in-Residence at Cancer Research Horizons, advising on early-stage investments rooted in research from Cancer Research UK. Throughout Jonathan's career, diverse Non-Executive Director roles have been undertaken at multiple organizations, including Adendra Therapeutics, AstronauTx, Myricx Pharma Ltd, CatalYm GmbH, NRG Therapeutics, and Pheon Therapeutics. Jonathan is also a member of the Investment Advisory Committee for the KHAN Technology Transfer Fund I, promoting early-stage drug discovery projects in Germany and Austria. Jonathan's academic background includes a MA in Biological Science from the University of Oxford, a PhD in Molecular Medicine from UCL, and an MBA from Imperial College London.